Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 4

1(16.7%)

6Total

N/A(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05851430Recruiting

Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry

Role: lead

NCT07487064Not ApplicableRecruiting

Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study

Role: lead

NCT07487844Not ApplicableNot Yet Recruiting

Pulsed Electric Field Ablation for Metastatic Breast Cancer

Role: collaborator

NCT05890872Not ApplicableCompleted

Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer

Role: lead

NCT04773275Not ApplicableTerminated

A Clinical Evaluation of the Aliya™ System in Late Stage Cancer

Role: lead

NCT04732520Not ApplicableCompleted

Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer

Role: lead

NCT05583188Phase 4Terminated

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Role: lead

All 7 trials loaded